We are a clinical-stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. Although we believe our approaches have broad potential across multiple therapeutic areas, we are focused in oncology and have engineered our technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells, or CTLs, to fight cancer. Our two primary product candidates, CMB305 and G100, utilize distinct immuno-oncology approaches that, we believe, address the shortcomings of existing therapies and have the potential to treat a broad patient population either as individual therapies or in combination with other mechanisms of action.
Our immuno-oncology product candidates are being developed in two separate approaches: one that targets specific antigens and/or epitopes (such as CMB305 and in our neoantigen collaboration); and an alternative approach that leverages the endogenous antigens found in the tumor microenvironment via intratumoral immunization (such as G100). The specific antigen approach uses selected antigens that are also present in the patient’s tumor so that the immune system will be educated to recognize the tumor antigen and kill tumor cells expressing the antigen. The intratumoral immunization approach, in contrast, does not require pre-identifying a selected antigen present in the tumor. It instead relies on treatments such as chemotherapy or local radiation to lyse tumors and release endogenous antigens, which are then captured by neighboring G100-activated dendritic cells, and is intended to generate a broad and varied immune response. Although they have distinct mechanisms of action, we designed both CMB305 and G100 to convert “cold” tumors, or those without CTLs, to “hot” tumors, or those with CTLs specific for the antigens expressed by the tumor.
While our primary focus is immuno-oncology, we believe that our platforms also have therapeutic potential in infectious and allergic diseases, and have multiple collaborations in place with global pharmaceutical companies leveraging the GLAAS platform. We look to our partnerships to provide potential downstream economics while preserving growth opportunities in the future.
(please see our Pipeline and Partners pages)